The effects of lipoic acid and dihydrolipoic acid were explored on total thiol maintenance in diabetic and non-diabetic human erythrocytes in vitro over 22 hr in a 37 ° C incubation system with no added glucose. Over 18 -22.5 hr after treatment in both non-diabetic and diabetic cells, lipoic acid (1 mM) was associated with greater loss of cellular thiols than dihydrolipoic acid (1 mM), compared to respective control values. At 0.1 mM, in non-diabetic cells, although lipoic acid-treated cells' thiol levels were significantly lower than control, there was no significant difference between dihydrolipoic acid-treated cells and control cells regarding thiol levels. In addition, at 0.1 mM, dihydrolipoic acid-treated diabetic cells showed a reduction in thiol levels compared to control. At 0.01 mM, lipoic acid-treated cells had significantly lower measured thiol levels compared with diabetic cells exposed to dihydrolipoic acid, whereas in non-diabetic cells, dihydrolipoic acid-treated erythrocytic thiol levels were significantly greater than those treated with lipoic acid, although there were no other significant differences between the groups. At 22.5 hr, control values of methaemoglobin rose to 6.4 ± 1.1% in diabetic cells and 3.6 ± 2.1% in non-diabetic cells. Lipoic acid (1 mM) showed greater methaemoglobin formation in diabetic rather than non-diabetic cells (13.6 ± 1.5% versus 11.6 ± 1.5%), whereas dihydrolipoic acid-treated diabetic and non-diabetic cells were less potent in methaemoglobin generation (8.5 ± 2.4% and 8.4 ± 1.4%, respectively). These studies suggest that in certain circumstances such as hypoglycaemia, lipoic acid administration may actually be detrimental to cellular oxidant protection status.The pathologies of several disease states are strongly linked with oxidative stress, and nutraceuticals such as lipoic acid (1,2-dithiolane-3-pentanoic acid) have been applied experimentally and clinically in the alleviation of these conditions. Lipoic acid has been used extensively in the treatment of diabetic complications [1,2], as well as the possible prevention of long-term diabetic toxicity [3]. Recent reports have focussed on the potential benefits of lipoic acid in conditions involving autoimmune disease [4,5], as well as exerciseinduced stress and tissue ageing [6,7]. Lipoic acid and its reduced form, dihydrolipoic acid, are both capable of acting as antioxidants, although it is only practical to administer lipoic acid clinically from the standpoints of toxicity and cost [8,9]. Once administered to mammalian cells, lipoic acid can be converted to dihydrolipoic acid by one of the major enzymes of the glutathione (GSH) system, oxidized glutathione (GSSG)-reductase [10].However, clinical antioxidant performance has often not been optimal, which is partly due to a lack of understanding of the molecular mechanisms of antioxidant function in human cells [8]. This situation is compounded by the strong influence of experimental conditions and design on perceptions of antioxidant performance [11]. In...